Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction

被引:93
作者
Peeters, Karlien [1 ]
Sahai, Arun [2 ,3 ]
De Ridder, Dirk [1 ,4 ]
Van der Aa, Frank [1 ,4 ]
机构
[1] Katholieke Univ Leuven Hosp, Dept Urol, Louvain, Belgium
[2] Guys Hosp, Dept Urol, London SE1 9RT, England
[3] KCL Sch Med, London, England
[4] Katholieke Univ Leuven, Dept Dev & Regenerat, Louvain, Belgium
关键词
idiopathic retention; Interstim (TM); voiding dysfunction; lower urinary tract dysfunction; overactive bladder; sacral neuromodulation; Fowler's syndrome; urgency frequency syndrome; urgency incontinence; TINED LEAD PROCEDURE; VOIDING DYSFUNCTION; OVERACTIVE BLADDER; NERVE-STIMULATION; EXPERIENCE; MANAGEMENT; THERAPY;
D O I
10.1111/bju.12571
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To report our long-term experience of sacral neuromodulation (SNM) for various lower urinary tract dysfunctions but with a focus on efficacy, safety, re-interventions and degree of success. Patients and Methods This is a single tertiary referral centre study that included 217 patients (86% female) who received an implantable pulse generator (IPG) (Interstim (TM), Medtronic, Minneapolis, USA) between 1996 and 2010. Success was considered if the initial >= 50% improvement in any of primary voiding diary variables persisted compared with baseline, but was further stratified. Results The mean duration of follow-up was 46.88 months. Success and cure rates were approximate to 70% and 20% for urgency incontinence, 68% and 33% for urgency frequency syndrome and 73% and 58% for idiopathic retention. In those patients with an unsuccessful therapy outcome, the mean time to failure was 24.6 months after implantation. There were 88 (41%) patients who had at least one device or treatment related surgical re-intervention. The re-intervention rate was 1.7 per patient with most of them (47%) occurring <= 2 years of follow-up. Conclusions SNM appears effective in the long-term with a success rate after definitive IPG implant of approximate to 70% and complete cure rates ranging between 20% and 58% depending on indication. Patients with idiopathic retention appear to do best. The re-intervention rate is high with most occurring <= 2 years of implantation. It is likely that with the newer techniques used, efficacy and re-intervention rates will improve.
引用
收藏
页码:789 / 794
页数:6
相关论文
共 21 条
[1]   Long-Term Outcome and Surgical Interventions After Sacral Neuromodulation Implant for Lower Urinary Tract Symptoms: 14-Year Experience at 1 Center [J].
Al-Zahrani, Ali A. ;
Elzayat, Ehab A. ;
Gajewski, Jerzy B. .
JOURNAL OF UROLOGY, 2011, 185 (03) :981-986
[2]   How Does Neuromodulation Work [J].
Amend, Bastian ;
Matzel, Klaus E. ;
Abrams, Paul ;
de Groat, William C. ;
Sievert, Karl-Dietrich .
NEUROUROLOGY AND URODYNAMICS, 2011, 30 (05) :762-765
[3]   Cost-Effectiveness of Sacral Neuromodulation Compared to Botulinum Neurotoxin A or Continued Medical Management in Refractory Overactive Bladder [J].
Arlandis, Salvador ;
Castro, David ;
Errando, Carlos ;
Fernandez, Eldiberto ;
Jimenez, Miguel ;
Gonzalez, Paloma ;
Crespo, Carlos ;
Staeuble, Funke ;
Manuel Rodriguez, Jose ;
Brosa, Max .
VALUE IN HEALTH, 2011, 14 (02) :219-228
[4]   An update on sacral neuromodulation: where do we stand with this in the management of lower urinary tract dysfunction in 2010? [J].
Bosch, J. L. H. Ruud .
BJU INTERNATIONAL, 2010, 106 (10) :1432-1442
[5]   Sacral neurostimulation for urinary retention: 10-year experience from one UK centre [J].
Datta, Soumendra N. ;
Chaliha, Charlotte ;
Singh, Anubha ;
Gonzales, Gwen ;
Mishra, Vibhash C. ;
Kavia, Rajesh B. C. ;
Kitchen, Neil ;
Fowler, Clare J. ;
Elneil, Sohier .
BJU INTERNATIONAL, 2008, 101 (02) :192-196
[6]   Improving neuromodulation technique for refractory voiding dysfunctions: Two-stage implant [J].
Janknegt, RA ;
Weil, EHJ ;
Eerdmans, PHA .
UROLOGY, 1997, 49 (03) :358-362
[7]   PNE Versus 1st Stage Tined Lead Procedure: A Direct Comparison to Select the Most Sensitive Test Method to Identify Patients Suitable for Sacral Neuromodulation Therapy [J].
Leong, Randall K. ;
De Wachter, Stefan G. G. ;
Nieman, F. H. M. ;
de Bie, Rob A. ;
van Kerrebroeck, Philip E. V. .
NEUROUROLOGY AND URODYNAMICS, 2011, 30 (07) :1249-1252
[8]   Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder [J].
Leong, Randall K. ;
de Wachter, Stephan G. G. ;
Joore, Manuela A. ;
van Kerrebroeck, Philip E. V. .
BJU INTERNATIONAL, 2011, 108 (04) :558-564
[9]  
Lucas MG, 2012, EUR UROL, V62, P1118, DOI [10.1016/j.eururo.2012.09.023, 10.1016/j.acuro.2013.02.002]
[10]   Is the Screening Method of Sacral Neuromodulation a Prognostic Factor for Long-Term Success? [J].
Marcelissen, Tom ;
Leong, Randall ;
Serroyen, Jan ;
van Kerrebroeck, Philip ;
de Wachter, Stefan .
JOURNAL OF UROLOGY, 2011, 185 (02) :583-587